Both Aclaris Therapeutics Inc. (NASDAQ:ACRS) and EyeGate Pharmaceuticals Inc. (NASDAQ:EYEG) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics Inc.	10.09M	26.22	132.74M	-3.85	0.00
EyeGate Pharmaceuticals Inc.	1.65M	9.24	10.81M	-0.45	0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 shows Aclaris Therapeutics Inc. and EyeGate Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics Inc.	-1,315.56%	-62.8%	-55.6%
EyeGate Pharmaceuticals Inc.	-655.15%	-158.8%	-72.7%

Volatility & Risk

Aclaris Therapeutics Inc. is 22.00% more volatile than S&P 500 due to its 1.22 beta. Competitively, EyeGate Pharmaceuticals Inc. is 133.00% more volatile than S&P 500, because of the 2.33 beta.

Liquidity

The Current Ratio and a Quick Ratio of Aclaris Therapeutics Inc. are 6.5 and 6.5. Competitively, EyeGate Pharmaceuticals Inc. has 2.5 and 2.5 for Current and Quick Ratio. Aclaris Therapeutics Inc.’s better ability to pay short and long-term obligations than EyeGate Pharmaceuticals Inc.

Institutional & Insider Ownership

Aclaris Therapeutics Inc. and EyeGate Pharmaceuticals Inc. has shares held by institutional investors as follows: 96.8% and 49.8%. Insiders held roughly 4.3% of Aclaris Therapeutics Inc.’s shares. Insiders Comparatively, held 14.69% of EyeGate Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Aclaris Therapeutics Inc.	3.65%	-2.3%	-21.72%	-56.54%	-65.15%	-7.85%
EyeGate Pharmaceuticals Inc.	0.23%	-9.52%	-17.29%	-22.3%	-25.59%	-5.61%

For the past year Aclaris Therapeutics Inc. was more bearish than EyeGate Pharmaceuticals Inc.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts. In addition, it is developing JAK inhibitors, including ATI-50001 that has completed Phase I clinical trial for the oral treatment of alopecia totalis and alopecia universalis; and ATI-50002, which has completed Phase I clinical trial for the topical treatment of patchy autoimmune dermatologic condition. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions. In addition, the company is developing Eyegate II drug delivery system. It has license agreements with the University of Miami and its School of Medicine; subsidiaries of Valeant Pharmaceuticals International, Inc.; BioTime, Inc.; and the University of Utah Research Foundation. Eyegate Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts.